```json
{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "I",
          "alt": "T",
          "position": "2020"
        },
        "variant_string_id": "LRRK2 I2020T"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Mutations in leucine-rich repeat kinase 2 (LRRK2) are a frequent cause of late-onset autosomal dominant Parkinson's disease (PD). Some disease-associated mutations directly affect LRRK2 kinase activity and inhibition of LRRK2 is viewed as a potential therapeutic treatment for PD.",
          "judgment": "Yes",
          "reasoning": "The paper states that mutations in LRRK2 are a frequent cause of PD, implying a loss-of-function or gain-of-toxic-function mechanism due to altered kinase activity, which makes it relevant to the functional assay.",
          "next_step_or_outcome": "Proceed to Step 2"
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "We demonstrate by both binding and enzymatic assays that alterations in the kinase activity of the PD-associated mutants I2020T and G2019S are due in part to altered ATP affinity.",
          "judgment": "Yes",
          "reasoning": "Kinase activity and ATP binding assays are directly relevant to the disease mechanism involving altered LRRK2 kinase function.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "All assays were performed using either three or four replicates for each data point represented.",
          "judgment": "Yes",
          "reasoning": "The paper states that the assays were performed with 3-4 replicates for each data point.",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Step 3c: Variant Controls",
          "extracted_paper_info": "We sought to investigate this potential issue by examining the ATP and inhibitor affinities for wild-type, G2019S, and I2020T.",
          "judgment": "No",
          "reasoning": "The paper did not use known pathogenic or benign variants as controls. The study compared the I2020T and G2019S variants to wild-type LRRK2 only.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting / Max BS3_supporting."
        },
        {
          "step_name": "Step 4a: Statistical Analyses",
          "extracted_paper_info": "Curve fitting and data analysis were performed with GraphPad Prism software (GraphPad Software, Inc., San Diego, CA).",
          "judgment": "No",
          "reasoning": "While the paper mentions statistical analyses were performed, there is no mention of calculation of OddsPath.",
          "next_step_or_outcome": "Proceed to Sub-step 4b"
        },
        {
          "step_name": "Step 4b: No OddsPath Calculation",
          "extracted_paper_info": "We sought to investigate this potential issue by examining the ATP and inhibitor affinities for wild-type, G2019S, and I2020T.",
          "judgment": "No",
          "reasoning": "The number of pathogenic/benign variant controls used in the study for the assay relevant to this variant is zero, which is less than 11.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting / Max BS3_supporting."
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The LRRK2 I2020T variant shows resistance to inhibition by ATP-competitive inhibitors, suggesting a damaging impact to normal protein function and potential pathogenicity. Since variant controls were not used and OddsPath was not calculated, and less than 11 pathogenic/benign controls were used, the strength is PS3_supporting."
    },
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "G",
          "alt": "S",
          "position": "2019"
        },
        "variant_string_id": "LRRK2 G2019S"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Mutations in leucine-rich repeat kinase 2 (LRRK2) are a frequent cause of late-onset autosomal dominant Parkinson's disease (PD). Some disease-associated mutations directly affect LRRK2 kinase activity and inhibition of LRRK2 is viewed as a potential therapeutic treatment for PD.",
          "judgment": "Yes",
          "reasoning": "The paper states that mutations in LRRK2 are a frequent cause of PD, implying a loss-of-function or gain-of-toxic-function mechanism due to altered kinase activity, which makes it relevant to the functional assay.",
          "next_step_or_outcome": "Proceed to Step 2"
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "We demonstrate by both binding and enzymatic assays that alterations in the kinase activity of the PD-associated mutants I2020T and G2019S are due in part to altered ATP affinity.",
          "judgment": "Yes",
          "reasoning": "Kinase activity and ATP binding assays are directly relevant to the disease mechanism involving altered LRRK2 kinase function.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "All assays were performed using either three or four replicates for each data point represented.",
          "judgment": "Yes",
          "reasoning": "The paper states that the assays were performed with 3-4 replicates for each data point.",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Step 3c: Variant Controls",
          "extracted_paper_info": "We sought to investigate this potential issue by examining the ATP and inhibitor affinities for wild-type, G2019S, and I2020T.",
          "judgment": "No",
          "reasoning": "The paper did not use known pathogenic or benign variants as controls. The study compared the G2019S and I2020T variants to wild-type LRRK2 only.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting / Max BS3_supporting."
        },
        {
          "step_name": "Step 4a: Statistical Analyses",
          "extracted_paper_info": "Curve fitting and data analysis were performed with GraphPad Prism software (GraphPad Software, Inc., San Diego, CA).",
          "judgment": "No",
          "reasoning": "While the paper mentions statistical analyses were performed, there is no mention of calculation of OddsPath.",
          "next_step_or_outcome": "Proceed to Sub-step 4b"
        },
        {
          "step_name": "Step 4b: No OddsPath Calculation",
          "extracted_paper_info": "We sought to investigate this potential issue by examining the ATP and inhibitor affinities for wild-type, G2019S, and I2020T.",
          "judgment": "No",
          "reasoning": "The number of pathogenic/benign variant controls used in the study for the assay relevant to this variant is zero, which is less than 11.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting / Max BS3_supporting."
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The LRRK2 G2019S variant shows sensitivity to inhibition by ATP-competitive inhibitors, suggesting a damaging impact to normal protein function and potential pathogenicity. Since variant controls were not used and OddsPath was not calculated, and less than 11 pathogenic/benign controls were used, the strength is PS3_supporting."
    }
  ]
}
```